Viking Therapeutics Inc
NASDAQ:VKTX

Watchlist Manager
Viking Therapeutics Inc Logo
Viking Therapeutics Inc
NASDAQ:VKTX
Watchlist
Price: 36.46 USD -1.94% Market Closed
Market Cap: 4.1B USD

Intrinsic Value

There is not enough data to reliably calculate the intrinsic value of VKTX.

The Intrinsic Value is calculated as the average of DCF and Relative values:

VKTX Intrinsic Value
Not Available
Base Case Scenario
Compare VKTX to

Fundamental Analysis

Company Overview
Loading...
Business Segments
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about VKTX?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Viking Therapeutics Inc

Current Assets 738.7m
Cash & Short-Term Investments 714.6m
Other Current Assets 24.1m
Non-Current Assets 712k
PP&E 666k
Other Non-Current Assets 46k
Current Liabilities 26.1m
Accounts Payable 4.4m
Accrued Liabilities 21.7m
Non-Current Liabilities 318k
Other Non-Current Liabilities 318k
Efficiency

Free Cash Flow Analysis
Viking Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Viking Therapeutics Inc

Revenue
0 USD
Operating Expenses
-274.8m USD
Operating Income
-274.8m USD
Other Expenses
37.4m USD
Net Income
-237.4m USD
Fundamental Scores

VKTX Profitability Score
Profitability Due Diligence

Viking Therapeutics Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.

ROE is Increasing
Low 3Y Average Gross Margin
Low 3Y Average Net Margin
Low 3Y Average Operating Margin
23/100
Profitability
Score

Viking Therapeutics Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.

VKTX Solvency Score
Solvency Due Diligence

Viking Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
81/100
Solvency
Score

Viking Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

VKTX Price Targets Summary
Viking Therapeutics Inc

Wall Street analysts forecast VKTX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for VKTX is 95.12 USD with a low forecast of 36.36 USD and a high forecast of 131.25 USD.

Lowest
Price Target
36.36 USD
0% Downside
Average
Price Target
95.12 USD
161% Upside
Highest
Price Target
131.25 USD
260% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Viking Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for VKTX is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

VKTX Insider Trading
Buy and sell transactions by insiders

VKTX News

Other Videos